查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1972095

心臟瓣膜牵开器市场：按产品类型、应用和最终用户划分－2026-2032年全球预测

Cardiac Valvulotome Market by Product Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，心臟瓣膜牵开器市场价值将达到 1.3318 亿美元，到 2026 年将成长至 1.4689 亿美元，到 2032 年将达到 1.9764 亿美元，复合年增长率为 5.80%。

主要市场统计数据
基准年 2025 1.3318亿美元
预计年份：2026年 1.4689亿美元
预测年份 2032 1.9764亿美元
复合年增长率 (%) 5.80%

基于资讯的心臟瓣膜牵开器引入：临床背景、设备发展历程以及影响引入和采购决策的因素。

瓣膜牵开器是一种用于治疗瓣膜性心臟病的专用器械，可透过微创或外科手术进行，其应用范围涵盖主动脉瓣、二尖瓣、肺动脉瓣和三尖瓣的介入治疗。随着人们越来越重视缩短手术时间、降低併发症发生率和改善病患復健情况，临床对精密器械的需求日益增长。因此，器械设计不断发展，更加重视人体工学、采用先进材料以及与混合手术室的兼容性，使临床医生能够将瓣膜牵开器整合到各种治疗方案中。

重塑心臟瓣膜切牙领域的关键变革因素是技术创新、医疗保健环境的变化以及不断变化的监管和报销重点。

由于技术进步、医疗实践的演变以及临床医生对能够提高手术精准度的器械日益增长的需求，心臟瓣膜牵开器的市场格局正在经历一场变革。小型化和材料科学的进步使得器械的截面尺寸更小、耐用性更高，并且能够实现创伤更小、可重复的手术操作，从而更好地适应临床路径。因此，能够与先进影像设备和混合手术环境配合使用的器械，正日益受到寻求更高控制力和更可预测手术结果的外科团队的青睐。

分析美国在 2025 年实施的关税政策对医疗设备相关人员的供应链韧性、采购重点和製造决策的累积影响。

美国于2025年实施的政策措施对整个医疗设备供应链产生了累积影响，波及製造、筹资策略和医院采购等各个环节。关税调整和贸易政策的变化影响了零件和成品的成本结构，迫使製造商重新评估与供应商的关係、国内生产的可能性以及库存缓衝方法，以维持供应的连续性并缓解成本波动。

实际的細項分析揭示了应用特殊性、最终用户环境以及一次性产品和可重复使用产品之间的选择如何驱动商业化和临床引入策略。

细分市场层面的洞察揭示了跨临床应用领域、医疗环境和产品原型的专业知识如何影响创新重点和商业化策略。主动脉瓣、二尖瓣、肺动脉瓣和三尖瓣疾病需要介入治疗的患者，需要使用根据解剖特征和细微手术差异量身定制的器械。为此，器械设计团队优化了叶片形状、轴桿柔软性以及与辅助器械的兼容性，以满足这些多样化的应用需求。因此，临床证据的产生通常按瓣膜类型分层，以证明每种解剖类型族群的疗效和安全性。

区域策略考量：强调医疗服务模式、监管多样性和供应现实如何对世界不同地区的实施产生不同的影响。

区域绩效模式反映了美洲、欧洲、中东和非洲以及亚太地区在医疗服务模式、法规环境和投资重点方面的差异。在美洲，综合医疗系统和专科心臟中心的集中发展推动了对支持高治疗能力、能够与先进影像设备和混合手术室整合的医疗设备的需求。临床医生网路和当地意见领袖在塑造新设备的推广应用路径和检验其有效性方面发挥着至关重要的作用。

产业竞争动态揭示了产品差异化、临床伙伴关係和供应策略如何决定临床医生的长期定位和采用。

心臟瓣膜切除器材领域的竞争格局取决于产品改进的渐进式策略、策略联盟以及对临床证据的定向投资。领先的研发企业致力于提升器材的人体工学设计、增强与影像系统的相容性，并拓展消毒流程的适应性。与临床中心建立合作关係以及参与研究者主导的临床研究，有助于提升市场信誉并提高外科医生的手术技能；同时，服务和培训计画也逐渐成为促进器械应用之外的差异化因素。

为製造商和医疗保健系统提供切实可行的优先建议，以加快采用速度、增强供应链韧性，并使商业模式与临床工作流程保持一致。

产业领导者应推动制定协调一致的策略，整合产品创新、临床工作流程优化、法规遵循规划和供应链韧性。优先采用模组化设计原则，使器械能够根据主动脉瓣、二尖瓣、肺动脉瓣和三尖瓣的特定需求进行调整，这将减轻临床医生的负担，并有助于产生有针对性的循证医学证据。同时，投资于全面的培训计画和指导，将增强临床医生的信心，并缩短他们掌握新器械所需的时间。

结合临床医师的访谈、监管审查和供应链分析的严谨混合调查方法，可得出经过验证的实用见解。

本报告的研究采用了一种混合方法，将定性一手研究与有针对性的二手资讯分析相结合，以获得精准且实用的见解。一手研究包括对心臟外科医生、采购负责人、临床技术人员和监管专家进行结构化访谈，以收集关于器械性能、采购标准和实施挑战的第一手观点。这些访谈内容与器械标籤材料、监管申报文件、同行评审的临床文献和技术白皮书相结合，建构出检验的、基于临床和监管背景的见解。

将设备创新、营运准备和供应保障与永续的临床部署和市场韧性联繫起来的策略结论进行简洁整合。

心臟瓣膜切除器材市场正处于转折点，器械的改进、医疗环境的变化以及政策的调整相互交织，为製造商和医疗系统带来了机会和挑战。器械团队若能根据主动脉瓣、二尖瓣、肺动脉瓣和三尖瓣每种介入治疗的解剖学特征设计器械，并针对各医疗机构（例如门诊手术中心、心臟中心、医院和专科诊所）的实际情况提供量身定制的支持，便能将临床研究成果转化为常规应用。同时，积极主动的供应链策略以及与医疗机构采购负责人的透明协作至关重要，有助于克服采购流程的复杂性，并应对关税造成的供应波动。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：心臟瓣膜牵开器市场：依产品类型划分

  • 一次性
  • 可重复使用的

第九章：心臟瓣膜牵开器市场：依应用领域划分

  • 主动脉瓣
  • 二尖瓣
  • 肺动脉瓣
  • 三尖瓣

第十章：心臟瓣膜牵开器市场：依最终用户划分

  • 门诊手术中心
  • 心臟中心
  • 医院
  • 专科诊所

第十一章：心臟瓣膜牵开器市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章：心臟瓣膜牵开器市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章：心臟瓣膜牵开器市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章：美国心臟瓣膜牵开器市场

第十五章：中国心臟瓣膜牵开器市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Andramed GmbH
  • B. Braun Melsungen AG
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • Cook Medical LLC
  • Edwards Lifesciences Corporation
  • Koven Technology Canada Inc.
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • Symmetry Surgical Inc
  • Teleflex Incorporated
  • Terumo Corporation
Product Code: MRR-2B5802CFEB49

The Cardiac Valvulotome Market was valued at USD 133.18 million in 2025 and is projected to grow to USD 146.89 million in 2026, with a CAGR of 5.80%, reaching USD 197.64 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 133.18 million
Estimated Year [2026] USD 146.89 million
Forecast Year [2032] USD 197.64 million
CAGR (%) 5.80%

An informed introduction to cardiac valvulotomes outlining clinical context, device evolution, and factors that influence adoption and procurement decisions

Cardiac valvulotomes are specialized instruments used in procedures to address valvular pathologies through minimally invasive or surgical approaches, and their relevance spans aortic, mitral, pulmonary, and tricuspid interventions. Clinical demand for precision tools has grown alongside an emphasis on shorter procedural times, reduced complication rates, and improved patient recovery profiles. Consequently, device design has evolved to prioritize ergonomics, cutting-edge materials, and compatibility with hybrid procedural suites, allowing clinicians to integrate valvulotomes within varied care pathways.

Technological advances have improved device tip design, visualization compatibility, and single-use sterility options, thereby influencing purchasing decisions across ambulatory surgery centers, cardiac centers, hospitals, and specialty clinics. As clinicians and procurement teams seek instruments that harmonize reliability with cost-effectiveness, the interplay between disposable and reusable product models becomes a focal point in deliberations. Transitioning from legacy devices to next-generation valvulotomes requires coordinated clinical validation, inventory management adjustments, and training initiatives to ensure safe, effective adoption.

Looking ahead, the intersection of procedural innovation, clinician preferences, and institutional purchasing priorities will determine adoption trajectories, with regulatory clarity and health-economic rationales serving as pivotal enablers for broader clinical uptake.

Key transformative forces reshaping the cardiac valvulotome landscape driven by technology, care setting migration, and evolving regulatory and reimbursement priorities

The landscape for cardiac valvulotomes is undergoing transformative shifts driven by technological refinement, evolving care settings, and rising clinician expectations for instruments that enhance procedural precision. Miniaturization and materials science breakthroughs have reduced cross-sectional profiles while improving durability, enabling interventions that are less invasive and better suited to repeatable clinical pathways. As a result, devices that integrate with advanced imaging modalities and hybrid operating environments are increasingly prioritized by surgical teams seeking greater control and predictable outcomes.

Simultaneously, the redistribution of cardiac services into ambulatory environments and specialty clinics is reshaping purchasing dynamics and inventory models. These changes prompt manufacturers to offer product portfolios that accommodate both single-use convenience and reusable cost efficiencies, along with targeted training and warranty structures. Regulatory and reimbursement frameworks are also adapting, with authorities emphasizing post-market surveillance and real-world evidence to validate safety and performance claims.

Taken together, these shifts create new imperatives for manufacturers, clinicians, and health systems to collaborate on clinical validation, workflow integration, and value communication. In this dynamic context, organizations that align innovation with pragmatic adoption support will secure stronger clinical endorsements and long-term integration into procedural standards.

An analysis of how 2025 United States tariff developments have cumulatively reshaped supply chain resilience, procurement priorities, and manufacturing decisions for device stakeholders

Policy measures enacted in the United States in 2025 have exerted cumulative effects across medical device supply chains, with implications for manufacturing, sourcing strategies, and hospital procurement. Tariff adjustments and trade policy shifts influenced the cost structures of components and finished devices, prompting manufacturers to reassess supplier relationships, onshore manufacturing potential, and inventory buffering practices to preserve continuity of supply and mitigate cost volatility.

As a result, procurement teams have increasingly emphasized supply chain resilience and supplier diversification. Hospitals and surgical centers now factor total landed cost and lead-time reliability into purchasing decisions more prominently than before, and device developers face heightened scrutiny regarding component provenance and manufacturing traceability. Moreover, the administrative burden associated with customs compliance and cross-border logistics has led some organizations to favor simplified device portfolios and to accelerate qualification of local suppliers.

In parallel, regulatory bodies and institutional contracting teams have sought greater transparency around unit cost drivers and lifecycle expenses. Consequently, manufacturers that proactively disclose supply chain strategies, offer flexible distribution models, and engage in collaborative contracting have preserved competitive positioning. Looking forward, these dynamics underscore the strategic importance of operational agility, predictable supply commitments, and clear communication with clinical and procurement stakeholders.

Actionable segmentation insights revealing how application specificity, end-user environment, and disposable versus reusable choices drive commercialization and clinical adoption strategies

Segment-level insights reveal how specialization by clinical application, care settings, and product archetypes informs both innovation priorities and commercialization strategies. Patients presenting with conditions requiring aortic, mitral, pulmonary, or tricuspid interventions demand instruments tailored to anatomical and procedural nuances, and device design teams have responded by optimizing blade geometry, shaft flexibility, and compatibility with adjunct devices to address these distinct application needs. Consequently, clinical evidence generation is often stratified by valve type to demonstrate efficacy and safety within each anatomic cohort.

End-user dynamics further influence product positioning. Ambulatory surgery centers, cardiac centers, hospitals, and specialty clinics exhibit different capital structures, procurement cycles, and inventory capacities, so manufacturers must calibrate pricing, service agreements, and training offerings to fit each setting. For example, ambulatory environments often prioritize rapid turnover and single-use convenience, whereas larger hospitals may assess total lifecycle costs and favor reusable systems that align with sterilization workflows. Product-type decisions therefore hinge on the trade-offs between disposability benefits, including infection control and simplified logistics, and reusable advantages such as lower per-procedure cost when sterilization workflows are optimized.

In sum, a thoughtful segmentation-driven approach to clinical validation, commercialization, and post-market support enables more precise alignment between device capabilities and the operational realities of diverse clinical environments.

Regional strategic observations emphasising how healthcare delivery models, regulatory diversity, and supply realities differently influence adoption across global territories

Regional performance patterns reflect distinct healthcare delivery models, regulatory environments, and investment priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, integrated health systems and a concentration of specialized cardiac centers have driven demand for devices that support high procedural throughput and integration with advanced imaging and hybrid suites. Clinician networks and regional opinion leaders play an outsized role in shaping adoption pathways and in validating new device entrants.

Across Europe, Middle East & Africa, procurement pathways and reimbursement policies vary substantially, prompting manufacturers to adopt differentiated market entry strategies and to invest in robust clinical evidence generation that satisfies diverse regulatory expectations. Regional distributors and local clinical champions are pivotal for navigating complex public and private payer landscapes. In the Asia-Pacific region, rapid healthcare infrastructure development in some markets has increased demand for scalable device solutions and for manufacturing partnerships that localize supply and reduce time to market.

Across all regions, interoperability with existing systems, training investments, and supply chain reliability remain universal priorities. Therefore, organizations that tailor toolkit bundles, education programs, and distribution models to regional nuances increase their probability of long-term adoption and better alignment with institutional priorities.

Industry competitive dynamics showing how product differentiation, clinical partnerships, and supply strategies determine long-term positioning and clinician uptake

Competitive dynamics in the cardiac valvulotome domain are defined by a combination of incremental product improvements, strategic collaborations, and targeted investments in clinical evidence. Leading developers have concentrated on refining device ergonomics, compatibility with imaging systems, and options that address sterilization workflows. Partnerships with clinical centers and participation in investigator-initiated studies have strengthened market credibility and facilitated surgeon familiarity, while service and training programs have emerged as differentiating offerings that support adoption beyond the device itself.

In addition, supply chain strategies and manufacturing footprints are increasingly strategic levers. Companies that demonstrate transparent sourcing practices and offer flexible distribution or consignment models find alignment with hospital procurement teams that prioritize supply certainty. Intellectual property and regulatory compliance investments remain critical for defending competitive positions, and M&A activity continues to be a tactical route for acquiring niche technologies or scaling distribution capacity rapidly.

In this environment, companies that balance technical differentiation with pragmatic adoption support-such as hands-on training, robust post-market surveillance, and responsive customer service-are better placed to secure clinician trust and to integrate their products into routine procedural algorithms.

Practical and prioritized recommendations for manufacturers and health systems to accelerate adoption, strengthen supply resilience, and align commercial models with clinical workflows

Industry leaders should pursue a coordinated strategy that aligns product innovation with clinical workflow optimization, regulatory planning, and supply chain resilience. Prioritizing modular design principles that allow device variants to address aortic, mitral, pulmonary, and tricuspid needs reduces complexity for clinicians while enabling targeted evidence generation. Concurrently, investing in comprehensive training programs and proctoring builds clinician confidence and shortens the learning curve for new devices.

Procurement-focused initiatives should emphasize transparent lifecycle cost analyses, flexible contracting options, and localized distribution arrangements to reduce exposure to tariff-driven cost fluctuations and logistic delays. Manufacturers can also mitigate risk by diversifying supplier networks and by qualifying alternative manufacturing sites to shorten lead times. To accelerate market acceptance, companies should partner with high-volume clinical centers to develop real-world evidence and to publish outcomes that resonate with both clinicians and payers.

Finally, establishing robust post-market surveillance and feedback loops enables continuous product improvement and strengthens regulatory dossiers. By integrating clinical, operational, and commercial strategies, industry leaders can convert innovation into sustainable adoption and position their organizations to respond quickly to evolving clinical and policy environments.

A rigorous mixed-methods research approach combining clinician interviews, regulatory review, and supply chain mapping to produce validated practical insights

The research underpinning this report employed a mixed-methods approach combining primary qualitative engagement with targeted secondary source analysis to produce nuanced, actionable insights. Primary inputs included structured interviews with cardiac surgeons, procurement officers, clinical engineers, and regulatory specialists to capture frontline perspectives on device performance, purchasing considerations, and implementation challenges. These conversations were synthesized with device labeling, regulatory filings, peer-reviewed clinical literature, and technical white papers to ground findings in verifiable clinical and regulatory context.

Analytical methods included thematic coding of interview data to identify recurring adoption barriers and enablers, crosswalks between procedural workflows and device features, and supply chain mapping to assess exposure to logistics and tariff pressures. Quality assurance measures included triangulation of primary inputs with independent secondary sources and iterative validation of findings through expert review panels. Wherever possible, comparisons across clinical settings and geographic regions were drawn to ensure the conclusions reflect diverse operational realities.

This methodology balances depth of clinician insight with breadth of secondary validation to provide practitioners and decision-makers with pragmatic guidance that is rooted in observed practice patterns and regulatory frameworks.

A concise synthesis of strategic conclusions tying device innovation, operational readiness, and supply assurance to sustainable clinical adoption and market resilience

The cardiac valvulotome landscape is at an inflection point where device refinement, changing care settings, and policy shifts intersect to create both opportunities and challenges for manufacturers and health systems. Device teams that align design with the anatomical specificity of aortic, mitral, pulmonary, and tricuspid interventions, and that tailor support to the operational realities of ambulatory surgery centers, cardiac centers, hospitals, and specialty clinics, will be better prepared to convert clinical interest into routine use. Simultaneously, navigating procurement complexities and responding to tariff-driven supply dynamics require proactive supply chain strategies and transparent engagement with institutional buyers.

Ultimately, success will hinge on delivering demonstrable clinical value, ensuring logistic reliability, and providing robust training and post-market support. Stakeholders who build partnerships across clinical, operational, and regulatory domains will not only accelerate adoption but also create resilient pathways for sustained clinical impact. The next phase of market evolution will reward those that execute on multi-dimensional strategies that balance innovation with pragmatic, evidence-based adoption plans.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiac Valvulotome Market, by Product Type

  • 8.1. Disposable
  • 8.2. Reusable

9. Cardiac Valvulotome Market, by Application

  • 9.1. Aortic
  • 9.2. Mitral
  • 9.3. Pulmonary
  • 9.4. Tricuspid

10. Cardiac Valvulotome Market, by End User

  • 10.1. Ambulatory Surgery Centers
  • 10.2. Cardiac Centers
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Cardiac Valvulotome Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Cardiac Valvulotome Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Cardiac Valvulotome Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Cardiac Valvulotome Market

15. China Cardiac Valvulotome Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. Andramed GmbH
  • 16.7. B. Braun Melsungen AG
  • 16.8. Boston Scientific Corporation
  • 16.9. Cardinal Health, Inc.
  • 16.10. Cook Medical LLC
  • 16.11. Edwards Lifesciences Corporation
  • 16.12. Koven Technology Canada Inc.
  • 16.13. Medtronic plc
  • 16.14. Merit Medical Systems, Inc.
  • 16.15. Symmetry Surgical Inc
  • 16.16. Teleflex Incorporated
  • 16.17. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIAC VALVULOTOME MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CARDIAC VALVULOTOME MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES CARDIAC VALVULOTOME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA CARDIAC VALVULOTOME MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY DISPOSABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY DISPOSABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY DISPOSABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY REUSABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY REUSABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY REUSABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY AORTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY AORTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY AORTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY MITRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY MITRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY MITRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY PULMONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY PULMONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY PULMONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY TRICUSPID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY TRICUSPID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY TRICUSPID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. AMERICAS CARDIAC VALVULOTOME MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 37. AMERICAS CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 38. AMERICAS CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 39. AMERICAS CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. NORTH AMERICA CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. NORTH AMERICA CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 42. NORTH AMERICA CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 44. LATIN AMERICA CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. LATIN AMERICA CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. LATIN AMERICA CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. EUROPE, MIDDLE EAST & AFRICA CARDIAC VALVULOTOME MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 49. EUROPE, MIDDLE EAST & AFRICA CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. EUROPE, MIDDLE EAST & AFRICA CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 51. EUROPE, MIDDLE EAST & AFRICA CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. MIDDLE EAST CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. MIDDLE EAST CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. MIDDLE EAST CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 59. MIDDLE EAST CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. AFRICA CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. AFRICA CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. AFRICA CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. AFRICA CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. ASEAN CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. ASEAN CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. ASEAN CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. ASEAN CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. GCC CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GCC CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. GCC CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. GCC CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPEAN UNION CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPEAN UNION CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPEAN UNION CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPEAN UNION CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. BRICS CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. BRICS CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. BRICS CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. BRICS CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. G7 CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. G7 CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. G7 CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. G7 CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. NATO CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NATO CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NATO CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. NATO CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. UNITED STATES CARDIAC VALVULOTOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 95. UNITED STATES CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. UNITED STATES CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. UNITED STATES CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. CHINA CARDIAC VALVULOTOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 99. CHINA CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. CHINA CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. CHINA CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)